公开(公告)号：US20200024346A1

公开(公告)日：2020-01-23

申请号：US16513002

申请日：2019-07-16

Applicant: UCB BIOPHARMA SPRL

Inventor： Helene Margaret FINNEY ,  Stephen Edward RAPECKI ,  Michael John WRIGHT ,  Kerry Louise TYSON

IPC: C07K16/28 ,  C07K16/18

Abstract: The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.

公开(公告)号：US20180172702A1

公开(公告)日：2018-06-21

申请号：US15736520

申请日：2015-10-22

Applicant: UCB Biopharma SPRL

Inventor： James Philip O'CONNELL ,  John Robert PORTER ,  Alastair LAWSON ,  Boris KROEPLIEN ,  Stephen Edward RAPECKI ,  Timothy John NORMAN ,  Graham John WARRELLOW

IPC: G01N33/68

Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.

公开(公告)号：US20190322739A1

公开(公告)日：2019-10-24

申请号：US16402097

申请日：2019-05-02

Applicant: UCB BIOPHARMA SPRL

Inventor： Helene Margaret FINNEY ,  Stephen Edward RAPECKI ,  Michael John WRIGHT

IPC: C07K16/28 ,  C07K16/14 ,  C07K16/46 ,  C07K16/00 ,  G01N33/68

Abstract: The present disclosure relates to a novel bispecific protein complex and a method of using the complexes to screen for synergistic or novel biological function. The bispecific format is particularly suitable for high-throughput screening because all of its components can be expressed from cells as individual units and the units can be assembled simply by mixing without employing conjugation or coupling chemistry.

公开(公告)号：US20180346604A1

公开(公告)日：2018-12-06

申请号：US15779426

申请日：2016-12-01

Applicant: UCB BIOPHARMA SPRL

Inventor： Stephen Edward RAPECKI

IPC: C07K16/46 ,  C07K14/39 ,  C07K16/14 ,  G01N33/68

CPC classification number: C07K16/468 ,  C07K14/39 ,  C07K16/00 ,  C07K16/14 ,  C07K2319/00 ,  G01N33/6854

Abstract: The present invention relates to a method of identifying, separating and characterizing a cell or a population of cells, by capturing at the cell surface, secreted soluble substances (such as an immunoglobulin) that cell or population of cell secrete. This is achieved by combing on a heterodimerically-tethered multispecific protein complex combining a binding specificity for the secreted molecule and a binding specificity for a surface antigen specific for that cell or population of cells. This method may be used in research and experimental purposes, such as patients' stratification in preparation of clinical trials or personalized therapies by identifying cell populations relevant to a pathology and/or prognosis.

公开(公告)号：US20180273620A1

公开(公告)日：2018-09-27

申请号：US15743756

申请日：2016-07-15

Applicant: UCB Biopharma SPRL

Inventor： Helene Margaret FINNEY ,  Stephen Edward RAPECKI ,  Kerry Louise TYSON ,  Michael John WRIGHT

IPC: C07K16/28

Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.

公开(公告)号：US20180237521A1

公开(公告)日：2018-08-23

申请号：US15743761

申请日：2016-07-15

Applicant: UCB Biopharma SPRL

Inventor： Helene Margaret FINNEY ,  Stephen Edward RAPECKI ,  Kerry Louise TYSON ,  Michael John WRIGHT

IPC: C07K16/28 ,  C07K16/18

CPC classification number: C07K16/289 ,  C07K16/18 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/90

Abstract: The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.

公开(公告)号：US20180231562A1

公开(公告)日：2018-08-16

申请号：US15736614

申请日：2015-10-22

Applicant: UCB Biopharma SPRL

Inventor： James Philip O'CONNELL ,  John Robert PORTER ,  Alastair LAWSON ,  Boris KROEPLIEN ,  Stephen Edward RAPECKI ,  Timothy John NORMAN ,  Graham John WARRELLOW ,  Tracy Lynn ARAKAKI ,  Alex Buntin BURGIN ,  William Ross PITT ,  Mark Daniel CALMIANO ,  David Andreas SCHUBERT ,  Daniel John LIGHTWOOD ,  Rebecca Jayne WOOTTON

IPC: G01N33/68 ,  C07K14/525 ,  C07K16/24 ,  C07D401/14 ,  C07D471/00 ,  A61P35/00 ,  A61P37/00

Abstract: A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.

公开(公告)号：US20180203016A1

公开(公告)日：2018-07-19

申请号：US15736336

申请日：2015-10-22

Applicant: UCB Biopharma SPRL

Inventor： James Philip O'CONNELL ,  John Robert PORTER ,  Alastair LAWSON ,  Boris KROEPLIEN ,  Stephen Edward RAPECKI ,  Timothy John NORMAN ,  David James MCMILLAN ,  Graham John WARRELLOW ,  Daniel Christopher BROOKINGS ,  Rikki Peter ALEXANDER

IPC: G01N33/68 ,  C07D471/04 ,  A61K47/64

CPC classification number: G01N33/6845 ,  A61K47/6425 ,  A61P35/00 ,  A61P37/00 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D401/14 ,  C07D471/00 ,  C07D471/04 ,  C07K14/525 ,  C07K14/70575 ,  C07K16/241 ,  C07K2317/55 ,  C07K2317/92 ,  G01N33/6854 ,  G01N33/6863 ,  G01N2333/525 ,  G01N2500/02

Abstract: The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.

公开(公告)号：US20180201678A1

公开(公告)日：2018-07-19

申请号：US15743764

申请日：2016-07-15

Applicant: UCB Biopharma SPRL

Inventor： Helene Margaret FINNEY ,  Stephen Edward RAPECKI ,  Kerry Louise TYSON ,  Michael John WRIGHT

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  A61K47/6809 ,  A61K47/6849 ,  A61K47/6867 ,  C07K16/18 ,  C07K16/289 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/76

Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD79, said binding domain comprising SEQ ID NO: 1, 2, 3 or 4, and/or SEQ ID NO: 5, 6 and 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.